Pierre Arty
Psychiatry · Brooklyn, NYNPI 1912983222
Payments from drug & device makers
Across 187 payments — averaging $33.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$710
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$293
- plus $746 from 9 others
What the payments were for
- Food & beverage$6,10098%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 62 | $1,341 |
| Alkermes, Inc. | 20 | $1,090 |
| Otsuka America Pharmaceutical, Inc. | 29 | $1,034 |
| Teva Pharmaceuticals USA, Inc. | 28 | $1,022 |
| Johnson & Johnson(2 entities) | 12 | $710 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $293 |
| Lundbeck LLC | 8 | $169 |
| E.r. Squibb & Sons, L.L.C. | 3 | $136 |
| Indivior Inc. | 6 | $134 |
| Viiv Healthcare Company | 5 | $117 |
| Sunovion Pharmaceuticals Inc. | 5 | $74 |
| AbbVie | 2 | $47 |
| Gilead | 1 | $30 |
| Corium, LLC | 1 | $24 |
| EMD Serono, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,476
- LYBALVI$1,452
- SPRAVATO$513
- ABILIFY MAINTENA$375
- ARISTADA INITIO$369
- CAPLYTA$254
- REXULTI$250
- INGREZZA$237
- AUSTEDO$225
- UZEDY$128
- COBENFY$122
- Austedo XR$113
How this compares
$6,235 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 13 | $28,557 |
| PristiqDesvenlafaxine Succinate | 12 | $5,029 |
| Lurasidone Hcl | 11 | $3,827 |
| Ramelteon | 15 | $1,218 |
| Sertraline Hcl | 45 | $1,055 |
| Quetiapine Fumarate | 76 | $882 |
| Buspirone Hcl | 44 | $809 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 20 | $750 |
| Aripiprazole | 77 | $698 |
| Gabapentin | 77 | $535 |
| Mirtazapine | 60 | $478 |
| Prazosin Hcl | 43 | $375 |
| Alprazolam | 58 | $344 |
| Bupropion XlBupropion Hcl | 43 | $325 |
| Clonazepam | 53 | $255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,034 | $28,55713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Brooklyn
- Inna Yuryev-GolgerBrooklyn$3M
- Zinoviy BenzarBrooklyn$505K
- Nikhil PalekarBrooklyn$481K
- Mark OwensBrooklyn$286K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.